Oculis Holding AG reported its financial results for the second quarter ended June 30, 2025, on August 25, 2025. The company announced revenues of $0.32 million for the quarter, an increase from $0.27 million in the corresponding period of 2024. However, the net loss for Q2 2025 widened to CHF 25.4 million, representing a 22% increase compared to the second quarter of 2024.
Research and Development (R&D) expenses for the three months ended June 30, 2025, were $18.1 million, a slight decrease from $18.2 million in the prior-year quarter. General and Administrative (G&A) expenses increased to $7.4 million from $6.9 million in the same period of 2024. The year-to-date net loss for the six months ended June 30, 2025, was $67.9 million, compared to $41.5 million for the same period in 2024.
As of June 30, 2025, Oculis maintained a strong liquidity position with $201.3 million in cash, cash equivalents, and short-term investments. This cash position, bolstered by recent financing activities, is projected to provide a cash runway into early 2028, supporting the company's ongoing clinical development programs despite the widening net loss.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.